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Regional Thallium Uptake in Irreversible Defects
In their recent article about stress thallium imaging to assess myocardial viability, Dilsizian et all make the important point that most mild-to-moderate irreversible defects (on either redistribution or reinjection images) represent viable myocardium. This group reached a similar conclusion in a previous article in Circulation. 2 In the more recent article, the authors used a measurement of "differential uptake" of IlTl from redistribution to reinjection, as well as "IF-fluorodeoxyglucose uptake in a subgroup, as confirmatory evidence of viability. They proposed that a differential uptake >50% of the normal region might be useful as a criterion of viability in irreversible defects on redistribution images. There were some problems, however, with their calculations of differential uptake in irreversible defects. First, the number of defects appeared to proliferate from the overall group of 150 patients, who had 175 irreversible defects, to the smaller subgroup of 15 patients who had PET studies, in whom 169 irreversible defects were found. In the PET subgroup, 11% of mild-to-moderate defects had differential uptake <50%, whereas in the overall group with mild-to-moderate defects (Figure 3 ), no patient had differential uptake <53%. In addition, the definition of a defect was based on different criteria for the two groups: A normal subject range was used for the 150 patients, while a criterion of <85% of the region with maximum counts was used for the 15-patient subgroup.
Many laboratories now use reinjection before delayed imaging as a routine, so a measure of differential uptake is not possible. An additional problem that this group has previously noted is apparent worsening of a defect from redistribution to reinjection, which occurs in 10% of defects3 and could result in a defect appearing irreversible on the reinjection image but reversible on the redistribution image. This phenomenon has also been ascribed to differential uptake.3 In our own study,4 11% of patients having both redistribution and reinjection studies showed at least one defect apparently irreversible on reinjection images but reversible on redistribution images. This problem was not addressed in the most recent article.1
The authors' conclusion that a high (>50%) differential uptake of thallium after reinjection at rest is a marker of viability is probably correct, but essentially this is a measure of uptake of isotope under resting conditions. The information might better be obtained by measuring uptake in a single rest image. 
Reply
In reply to Dr. Freedman's first question, the apparently large number of irreversible thallium defects in the subgroup of 15 patients who had positron emission tomography (PET) studies compared with the overall group of 150 patients relates to the different methods of analysis used in the two patient groups. For the overall group, thallium activity was assessed in four myocardial regions (anterior, septal, inferior, and lateral) per patient, obtained from short-axis tomograms using a semiautomatic quantitative circumferential profile. This is clearly stated in the "Methods" section under "Quantitative Thallium Analysis."1 Because PET images in the subgroup of 15 patients were acquired in the transaxial view, the three sets of thallium images representing the stress, redistribution, and reinjection studies in each patient were aligned in the transaxial view for direct comparison. Relative regional 18F-fluorodeoxyglucose uptake and thallium activity were assessed in five myocardial regions drawn from corresponding transaxial tomograms: posterolateral, anterolateral, anteroapical, anteroseptal, and posteroseptal myocardium. Multiple corresponding myocardial slices from the PET and SPECT data were then analyzed for each patient, with an average of 29 regions (from six tomographic planes) evaluated per patient. This is also stated in the "Results" section under "Comparison of Differential Uptake With Metabolic Activity by PET."' Therefore, Dr. Freedman's second question regarding the different percentage of mild-to-moderate defects having differential uptake of <50% (11% for the PET subgroup versus 0% for the overall group) should not come as a surprise, because different anatomic regions were assessed in the overall group and the PET subgroup. The third question relates to the definition of a thallium defect. For the overall group, a myocardial region was considered abnormal if the thallium uptake on the stress image was >2 SD below the mean observed in the same region for normal volunteers of the same sex. Because the PET subgroup was assessed in the transaxial view, comparison with a normal data base in this orientation was not available. Thus, in keeping with our previous publication,2 a myocardial region with thallium activity of <85% of the region exhibiting the maximal activity over the entire myocardium was defined to be abnormal. We realize that many laboratories have adopted the routine practice of performing reinjection imaging instead of 3-4-hour redistribution imaging. However, we have never advocated the elimination of redistribution images. In our original article,3 we reported that approximately 10% of thallium defects on stress images develop apparent thallium washout after reinjection of thallium. The reason the subject of apparent thallium washout was not discussed again in the article in question' is that the aim of this study was different. The differential uptake ratio in this article was used to demonstrate that not all irreversible thallium defects connote scarred myocardium. We specifically addressed the issue of apparent thallium washout in a subsequent article involving a different series of patients,4 in which 8% of thallium defects identified on stress images demonstrated apparent thallium washout after reinjection because of low differential uptake of the tracer. These regions represented 25% of myocardial regions that were reversible on 3-4-hour redistribution and would have been incorrectly interpreted to be irreversible if only stress-reinjection images were acquired. Dr. Freedman's finding of low differential uptake in 11% of their patients after reinjection appears to confirm our results.
We agree with Dr. Freedman that similar information might be obtained if an analysis of thallium activity after a resting injection of 20`T1 were used. Preliminary data in our laboratory suggest a high concordance between the results of stress-redistributionreinjection imaging and rest-redistribution imaging. 5 We caution that a resting image alone may be insufficient and that a subsequent redistribution image after the injection at rest is often necessary. Letter To the Editor Beuckelmann et al recently published a report in Circulation' showing that peak systolic intracellular calcium measured by fura-2 was diminished in single ventricular cells from patients with heart failure. Although the experimental findings were interesting, the suggestion by the authors that the major defect in contractile failure is a diminished intracellular calcium concentration was distressing. The authors propose that diminished calcium availability might explain impaired contractile performance in human heart failure because calcium concentration is intimately related to force production; it is important to note, however, that this conclusion is weakened by the fact that Beuckelmann et al did not measure force or cell shortening during excitation in their cells. These results are in contrast to those obtained by other investigators who used different experimental techniques and reported similar systolic calcium concentrations in myopathic and control human myocardium.2-6 More importantly, we and others have found similar force production in control and myopathic hearts, and it has been clearly demonstrated that in failing human myocardium, there is a significant increase in resting intracellular calcium concentration. The clinical extrapolation of the data proposed by the authors was especially alarming because they suggest that agents that increase intracellular calcium would be beneficial in patients with failure. Recently, however, the PROMISE trials7 have indicated that such agents may not be useful or may even be harmful to patients with failure. We feel that it is very important to alert the reader that the issue of whether intracellular calcium release is reduced during excitation-contraction coupling in heart failure is still controversial and that therapeutic decisions should not be based on this one report.
We appreciate the comments by Dr. Morgan and Dr. Gwathmey concerning the interpretation of our data. There may have been some misunderstanding, however, as our results do not indicate a generally diminished intracellular [Ca21], concentration. In fact, we have shown that resting [Ca2+]J levels are increased but that peak systolic [Ca21]1 transients are diminished in heart cells from patients with heart failure. Therefore, we completely agree that pharmacological agents that would simply increase resting [Ca2+]1 might be harmful. An increase in resting [Ca 2+I1 might further reduce Ca2' release from the sarcoplasmic reticulum through Ca2+-dependent inactivation of the Ca2' release channel as shown by Fabiato.1 Therefore, in our paper we have put forward the idea that pharmacological agents that enhance Ca21 uptake by the sarcoplasmic reticulum would be expected to be beneficial, which agrees with suggestions in earlier papers from Drs. Morgan and Gwathmey. Whether such a pharmacological intervention is beneficial in heart failure, of course, has to await a clinical trial. from a patient with heart failure is shown. In that paper, however, no quantitative comparison between diseased and undiseased myocardium has been attempted. Therefore, we think that the
